Abeona Therapeutics’ Post

Thoughts on this? >> Flagship appears to boost target of 8th fund by up to $500M >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #biotech #pharmaceutical #productmarketing #healthcare

Thoughts on this? >> Flagship appears to boost target of 8th fund by up to $500M >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #productmarketing #pharma #pharmaceutical #biotech

Where's the next Cubic Telecoms? Get to know the new EIIS rules and gain 50% investment discounts, see lots of great early stage stories all year, and start building your own fund at your own size and speed... with NO fees. For a systematic and professional approach this EIIS Private Portfolio explainer could be a big help for 2024.... https://lnkd.in/gq2zuCaC ATXA Therapeutics Altach (an NLC Venture)

Exciting Developments in Biopharma! 🔬 RedHill Biopharma (RDHL) makes headlines with a 180% surge, driven by FDA approval for Talicia targeting H. pylori. 🚀 This groundbreaking therapeutic, granted a 5-year market exclusivity, has garnered attention from multiple hedge funds. Read the full story and explore the potential impact on RDHL stock: https://lnkd.in/ey5Nz2ye The fundamental case for RDHL centers on its potential in addressing a widespread health concern. H. pylori, a bacterial infection affecting over half the global population, presents a significant market opportunity. Despite the recent stock volatility, the strategic interest from hedge funds like Armistice Capital, Sabby Management, and others underscores confidence in RDHL's future. 🌐💼 It's crucial to acknowledge the risks, with RDHL having lost around 86% of its equity value this year. The absence of analyst coverage and identified red flags add a layer of complexity. However, the strategic investments by prominent hedge funds suggest a belief in the long-term potential. 💪📈 For a comprehensive overview of the latest developments and the nuanced landscape surrounding RDHL stock, dive into the detailed analysis: https://lnkd.in/ey5Nz2ye #Biopharma #InvestmentOpportunity #HealthcareInnovation #RDHLStock

Good news for Cybin!!

You're seeing the news on Merck & Co. ($MRK), but did you know it is a holding in $DIVO and $THNR? For complete list of holdings and fund info: Amplify CWP Enhanced Dividend Income ETF https://hubs.li/Q02y_d6p0 Amplify Weight Loss Drug & Treatment ETF https://hubs.li/Q02y_bps0

ICYMI: Shadd Dales and Anthony Varrell spoke to NewLake Capital Partners, Inc. CEO Anthony Coniglio over on The Dales Report to talk about the real estate investing side of the cannabis world, the potential of the Ohio market, and way, way more 🏢 Link to watch the whole thing in the comments 💻 And remember, we're going live at 4:10 PM EST 💪 #cannabis #cannabisbusiness #realestateinvestmenttrust

IMMURON LIMITED (NASDAQ:IMRN, ASX:IMC) has secured an At-the-Market (ATM) funding facility with HC Wainwright and Co LLC, which will provide the Australian biotech with around US$2 million in funding. The company has filed a Form F-3 registration statement and ATM prospectus with the United States Securities and Exchange Commission (SEC). The Form F-3 allows Immuron, as a 'foreign private issuer', to raise up to US$15 million in the United States over a three-year period. This supersedes the company's recently expired US$100 million Form F-3 announced on April 9, 2019. The Form F-3 maintains Immuron’s flexibility with direct access to US capital markets. ATM funding facilities are widely used in the US and are becoming commonplace in Australia. More at #Proactive #ProactiveInvestors #ASX #IMC #Biotech #SEC #AntibioticResistance http://ow.ly/3fZO105z6ho

Roivant (NASDAQ: ROIV) Gains Spotlight with Entry into S&P MidCap 400 Index https://lnkd.in/dfK7tpZ5 #roivant #stockmarket #stockmarketnews #BusinessNews #news #NewsAlert

Have you heard of Chromocell Therapeutics Corporation (NYSE American: CHRO)? 🤔 They just closed their initial public offering of 1,100,000 shares of their common stock at $6.00 per share, raising approximately $6.6 million. 💰 That’s a huge milestone for Chromocell Corporation. 🚀 They are a clinical-stage biotech company that is developing and commercializing new, non-opioid therapeutics to alleviate pain. 💊 This post is brought to you by Spiking Wealth Masterclass. Sign up for Early Bird at $0 now: https://spi.ke/mc25 They have a novel approach to target the sodium ion-channel known as NaV1.7, which is involved in various types of chronic neuropathic pain and eye pain. 👁️ They also have pre-clinical work on other sodium channel receptor subtypes and plan to explore them for the treatment of additional pain indications. 🔬 To get more updates on IPO, stock market, investment, and crypto currency, Follow Us! 😊 Also, don’t miss this chance to join the Spiking community and become a smart investor. 😎 Dr. Clemen Chiang (PhD, MBA) #CHRO #NYSE #IPO #Investing #Finance #FinancialEducation #FinancialSuccess #FinancialLiteracy #Trading #Spiking